Compare TG Therapeutics Inc (TGTX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vale SA — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Vale SA trades at $15.42 (market cap $65.56B). The key difference: Vale SA is far larger — about 7.7× TG Therapeutics Inc's market cap, and Vale SA pays a 7.65% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VALE | |
|---|---|---|
Market Cap | $8.53B | $65.56B |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $17.82 |
52-Week Low | $26.94 | $10.50 |
Enterprise Value | $8.74B | $81.80B |
Dividend Yield | — | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
VALE trades at $15.56, up 1.9% on the day, with a bullish technical signal from moving averages and a consensus price target of $16.79. Recent earnings missed estimates for Q4 2025 and Q1-Q2 2026, with net income margin declining to 5.11% in 2025. The company maintains strong operating cash flow of $8.80B and announced a $0.40 dividend for H2 2026. Iron ore demand remains stable per the CFO, while base metals growth offsets cost pressures.
VALE presents a mixed outlook: bullish technicals and analyst support contrast with earnings misses and margin compression. The stock offers value near consensus targets with dividend income, but faces risks from rising costs, volatile commodity prices, and legal liabilities from past dam incidents. Upside depends on execution in copper growth and cost control.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
